The capital will be used to expand the team, build out content, and launch a new multibook platform.
"Whether you want to become a better leader, better sleeper or reduce your anxiety, we all want to improve our lives. However we discovered the self-development market fails to deliver, not because the advice isn't good, but because information isn't enough. Our platform enables us to deliver interactive practices through mobile, so people can access tools to help them the moment they need them, whatever the situation. We have been thrilled with the support we have received from investors and some of the biggest self-development authors in the world as we look to scale our offering."
The healthtech startup has secured fresh backing to advance the artificial intelligence capabilities of its clinical trials platform.
"This next round of Innovate UK funding is a huge endorsement of everything we are achieving with Archer. For us, it’s always been about how we accelerate a major step-change in the speed, efficiency and affordability of clinical studies."
Gresham House Ventures led the £7m Series A investment to support primary and secondary care expansion.
"This funding will help us keep pace with the product development we need to support cutting edge health technology across both primary and secondary care. NHS patients deserve an excellent digital experience when interacting with the health service and we now look forward to delivering the transformation needed."
The financing round was led by IQ Capital with participation from Hambro Perks and Ascension Ventures.
"This latest round of investment is a great recognition of our customers' success through our breakthrough AI and a product focused approach. With our existing investors reaffirming their support of the company and new investors with vast experience in the life sciences industry coming on board, we are on course to achieve our core mission of improving patient outcomes through a highly profitable and sustainable business model. In the past 12 months, the company has grown 15 times through the successful deployment of PIE in the biopharmaceutical industry, partnerships with healthcare data providers and significant contributions to peer review publications, which demonstrates that we are leading in this sector. This funding will accelerate this success by providing the resources to strengthen the team, explore new use cases, and expand into new markets."
